Soluble Monomeric MIC Proteins for NK Cell Targeting

Solution Overview

Problem

Malignant cells and virus-infected cells often evade the innate immune system by avoiding expression of MIC proteins, leading to immune evasion and aggressive behavior, as they are not recognized by NK cells and certain T-cells.

Innovation Solution

Development of soluble, monomeric, non-natural protein molecules that recruit and activate NK cells by attaching the NKG2D-binding portions of MICA or MICB proteins to specific target molecules on malignant or virus-infected cells through a targeting motif with a heterologous peptide, directing the binding of the α1-α2 platform domain to the target cell.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If malignant cells avoid expression of MIC proteins, then they evade immune detection and survive, but they lose the ability to be recognized and destroyed by NK cells

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a bispecific antibody as an intermediary molecule that bridges the gap between NK cells and malignant cells. The antibody has one arm binding to NKG2D on NK cells and another arm binding to target antigens on malignant cells, thereby mediating the interaction and enabling immune recognition despite the cells' evasion mechanisms

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs preliminary action by pre-activating NK cells through engagement of NKG2D receptors with the bispecific antibody before the NK cells encounter the malignant cells. This preliminary activation ensures that NK cells are in an optimal state to immediately attack the target cells upon binding

Inventive Principle:
Principle #10Preliminary action

2Adaptability or versatility

If soluble MIC proteins are used to activate NK cells, then immune recognition is enhanced, but specificity to target cells may be reduced

Engineering Contradiction:
Core Design Contradiction:
Adaptability or versatilityVSManufacturing precision

Solution Approach 1:

The bisspecific antibody exhibits local quality by having different binding specificities at its two ends: one end specifically recognizes NKG2D on NK cells while the other end specifically recognizes target antigens on malignant cells. This localized specialization enables both broad NK cell activation and precise target cell selection simultaneously

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The invention uses a composite molecular structure combining two different antibody specificity domains into a single bispecific antibody molecule. This composite structure integrates the ability to bind NK cells with the ability to bind target cells, achieving both enhanced immune activation and maintained targeting precision

Inventive Principle:
Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified MIC proteins effectively target and activate NK cells to adhere to and destroy malignant or virus-infected cells, overcoming immune evasion mechanisms and enhancing immune recognition and attack.

Implementation Method 1

a heterologous peptide that directs the binding of the targeting motif to a target molecule on target cell

Methodology Applied
Scientific EffectMolecular recognition:

Implementation Method 2

NKG2D, a prominent, homodimeric, surface immunoreceptor responsible for recognizing a target cell and activating the innate defense

Methodology Applied
Scientific EffectReceptor-ligand binding:

Data Source

PatentUS8658765B2Non-natural MIC proteins
Publication Date: 2014.02.25
  • US8658765B2 patent drawing
  • US8658765B2 patent drawing
  • US8658765B2 patent drawing

AI summary

This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their α1-α2 platform domain, to the intended target cell specifically. The α1-α2 domain is contiguous with a heterologous α3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the α3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified α3 domain of a MIC protein.